Podophyllotoxin

The high recurrence rate of sexually transmitted skin diseases such as condyloma acuminatum and genital herpes has always been a therapeutic difficulty in clinical dermatology, and the clinical application of podophyllotoxin provides a precise topical treatment pathway for such diseases. As a plant-derived cytotoxic alkaloid, it can inhibit microtubule polymerization, block cell mitosis at the metaphase, and inhibit the DNA replication of herpes virus. It is mainly used clinically for the treatment of condyloma acuminatum on external genitalia and around the anus, and is a first-line topical therapeutic drug recommended by WHO. It is suitable for adult patients over 18 years old with normal immune function. After single administration, the local concentration is high, the systemic exposure is extremely low, and the adverse reactions are mostly mild local irritation.

The global market size of podophyllotoxin-related preparations was approximately USD 280 million in 2023, and the compound annual growth rate from 2024 to 2030 is expected to be 4.2%. The growth momentum mainly comes from the rising incidence of sexually transmitted diseases and the popularization of topical treatment regimens in primary medical care. The current market is dominated by generic drugs, with original research products accounting for less than 15%. China is the world's largest producer of podophyllotoxin API, with production capacity accounting for more than 75% of the global total. The domestic preparation market has completed the coverage of provincial-level centralized procurement, and the selected price has dropped by 68% compared with the original research product, greatly improving the accessibility of medication for patients.

The original research enterprise of podophyllotoxin is Suisse Pharma Care, and the original research trade name is "Wartec". Its core compound patent expired in 2002 in major global markets. The core dosage form of the original research product is 0.5% topical solution with a specification of 3ml per bottle, which has been included in the FDA Reference Listed Drug Catalog, and also included in the *Catalog of Reference Preparations for Chemical Drugs (Third Batch)* of China. In terms of domestic API registration, a total of 6 enterprises have obtained A-status registration numbers for podophyllotoxin API. Both 0.5% podophyllotoxin tincture and 0.5% podophyllotoxin ointment have been approved for marketing by the NMPA, and multiple domestic preparations have passed the consistency evaluation. (Data as of June 2025, please refer to the official website of CDE for the latest information)

In response to the quality research needs of podophyllotoxin API and preparations, CATO can provide a full set of impurity reference standards for this product, most of which are in stock regularly. Orders placed before 16:00 can be shipped on the same day. All reference standards meet the regulatory requirements of multiple countries such as the Chinese Pharmacopoeia and FDA, and can fully support enterprises' methodological validation, stability study and registration declaration work.